JP2010280687A5 - - Google Patents

Download PDF

Info

Publication number
JP2010280687A5
JP2010280687A5 JP2010169960A JP2010169960A JP2010280687A5 JP 2010280687 A5 JP2010280687 A5 JP 2010280687A5 JP 2010169960 A JP2010169960 A JP 2010169960A JP 2010169960 A JP2010169960 A JP 2010169960A JP 2010280687 A5 JP2010280687 A5 JP 2010280687A5
Authority
JP
Japan
Prior art keywords
active agent
less
surface stabilizer
particles
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010169960A
Other languages
English (en)
Other versions
JP2010280687A (ja
Filing date
Publication date
Priority claimed from US09/952,032 external-priority patent/US20030054042A1/en
Application filed filed Critical
Publication of JP2010280687A publication Critical patent/JP2010280687A/ja
Publication of JP2010280687A5 publication Critical patent/JP2010280687A5/ja
Pending legal-status Critical Current

Links

Claims (10)

  1. 活性剤を化学的に安定化する方法であって、
    (a)該方法は、加水分解、酸化、異性化、エピマー化および光分解からなる群から選ばれる化学反応によって起こされた活性剤の分解を減少させるものであり、ならびに/または、温度、光、放射線、酵素、触媒、活性剤を含む溶液のpHおよびイオン強度、活性剤を含む液体媒体に存在する溶媒のタイプ、ならびに活性剤を含む液体媒体に存在する緩衝剤の種類からなる群から選択される一つまたはそれ以上の環境要因によって影響を受けた活性剤の分解速度を減少させるものであり、
    (b) 該方法は、以下の段階を含み;
    (i)(a)の化学反応および/または環境要因によって化学的に不安定であって、水への溶解性に乏しい、少なくとも1種の活性剤を同定および選択する段階;ならびに
    (ii)活性剤の粒子を、少なくとも1種の表面安定剤に接触させて、活性剤の粒径を約2000nm未満の有効平均粒径とすることにより、ナノ粒子活性剤組成物を形成する段階であって、前記表面安定剤は、活性剤粒子の表面に吸着し、本質的に分子間架橋を含まない、段階;ならびに、
    (c)生成したナノ粒子活性剤組成物は、2日以上貯蔵された場合に、活性剤の出発濃度(strength)に対する活性剤の最終濃度が95%以上である、
    方法。
  2. 活性剤が、活性剤と表面安定剤との合計重量に基づいて、99.9%〜10%(w/w)の量で存在する、請求項記載の方法。
  3. 少なくとも1種の表面安定剤が、活性剤と表面安定剤との合計重量に基づいて、0.1〜90%(w/w)の量で存在する、請求項1または2記載の方法。
  4. 活性剤の粒子が、約1ミクロン未満、約600nm未満、約500nm未満、約400nm未満、約300nm未満、約200nm未満、約100nm未満、および約50nm未満からなる群から選ばれる有効平均粒径を有する、請求項1〜3のいずれか1項記載の方法。
  5. ナノ粒子活性剤組成物が注射可能な製剤である、請求項1〜4のいずれか1項記載の方法。
  6. 活性剤がラパマイシンである、請求項1〜5のいずれか1項記載の方法。
  7. 該ラパマイシンが、加水分解条件に曝された後で安定である、請求項6記載の方法。
  8. 活性剤がパクリタキセルである、請求項1〜5のいずれか1項記載の方法。
  9. 該パクリタキセルが、塩基性pH条件に曝された後で安定である、請求項8記載の方法。
  10. 活性剤粒子が結晶相、無定形相、半結晶相又はそれらの組合せである、請求項1記載の方法。
JP2010169960A 2001-09-14 2010-07-29 ナノ微粒子形態への製剤化による活性剤の安定化 Pending JP2010280687A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/952,032 US20030054042A1 (en) 2001-09-14 2001-09-14 Stabilization of chemical compounds using nanoparticulate formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003528521A Division JP2005505568A (ja) 2001-09-14 2002-09-13 ナノ微粒子形態への製剤化による活性剤の安定化

Publications (2)

Publication Number Publication Date
JP2010280687A JP2010280687A (ja) 2010-12-16
JP2010280687A5 true JP2010280687A5 (ja) 2011-10-20

Family

ID=25492513

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003528521A Pending JP2005505568A (ja) 2001-09-14 2002-09-13 ナノ微粒子形態への製剤化による活性剤の安定化
JP2010169960A Pending JP2010280687A (ja) 2001-09-14 2010-07-29 ナノ微粒子形態への製剤化による活性剤の安定化

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003528521A Pending JP2005505568A (ja) 2001-09-14 2002-09-13 ナノ微粒子形態への製剤化による活性剤の安定化

Country Status (11)

Country Link
US (4) US20030054042A1 (ja)
EP (2) EP1427395B1 (ja)
JP (2) JP2005505568A (ja)
AT (1) ATE388690T1 (ja)
CA (1) CA2460436C (ja)
CY (1) CY1108130T1 (ja)
DE (1) DE60225571T2 (ja)
DK (1) DK1427395T3 (ja)
ES (1) ES2303553T3 (ja)
PT (1) PT1427395E (ja)
WO (1) WO2003024424A1 (ja)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
EP1429749A2 (en) * 2001-09-26 2004-06-23 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
CA2548376A1 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
EP1781279A2 (de) * 2004-06-11 2007-05-09 Egon Tech Präparat zur prophylaxe und therapie von stresszuständen, von funktionellen und organischen störungen des nervensystems und des stoffwechsels
JP2006089386A (ja) * 2004-09-21 2006-04-06 Nippon Tenganyaku Kenkyusho:Kk ステロイドまたはステロイド誘導体を含有する懸濁性医薬組成物
US20060147515A1 (en) * 2004-12-02 2006-07-06 Zhongzhou Liu Bioactive dispersible formulation
US7727554B2 (en) * 2004-12-21 2010-06-01 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Sustained-release nanoparticle compositions and methods for using the same
US20090252807A1 (en) * 2005-04-13 2009-10-08 Elan Pharma International Limited Nanoparticulate and Controlled Release Compositions Comprising Prostaglandin Derivatives
AU2006344711A1 (en) * 2005-05-16 2008-01-24 Alkermes Pharma Ireland Limited Nanoparticulate and controlled release compositions comprising a cephalosporin
CA2608930A1 (en) * 2005-06-14 2006-12-28 Baxter International Inc. Pharmaceutical formulations for minimizing drug-drug interactions
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
JP2009516003A (ja) * 2005-11-15 2009-04-16 バクスター・インターナショナル・インコーポレイテッド リポキシゲナーゼ阻害剤の組成物
MX2008006888A (es) 2005-11-28 2008-09-30 Marinus Pharmaceuticals Formulas y metodos para la manufactura y uso de la ganaxolona.
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
NZ572207A (en) 2006-03-24 2012-02-24 Auxilium Int Holdings Inc Stabilized compositions containing alkaline labile drugs
CA2656277A1 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
EP2101735A2 (en) * 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
EP1938800A1 (en) * 2006-12-06 2008-07-02 Ranbaxy Laboratories Limited Sirolimus nanodispersion
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
PL2481402T3 (pl) * 2007-03-07 2018-11-30 Abraxis Bioscience, Llc Nanocząstka zawierająca rapamycynę i albuminę jako środek przeciwnowotworowy
WO2008137148A2 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
JP5579057B2 (ja) * 2007-06-01 2014-08-27 アブラクシス バイオサイエンス, エルエルシー 再発性癌の処置のための方法および組成物
KR101441523B1 (ko) * 2007-12-14 2014-09-17 에자끼구리고가부시키가이샤 α-리포산 나노입자들 및 이의 제조 방법
EP2249808A2 (en) * 2008-01-11 2010-11-17 Cipla Limited Solid pharmaceutical dosage form
EP2268833A1 (en) * 2008-03-12 2011-01-05 Do-Coop Technologies Ltd Freeze-free method for storage of polypeptides
CN102026621A (zh) * 2008-05-15 2011-04-20 巴克斯特国际公司 稳定的药物制剂
US20100098770A1 (en) * 2008-10-16 2010-04-22 Manikandan Ramalingam Sirolimus pharmaceutical formulations
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
EA201101530A1 (ru) * 2009-04-21 2012-03-30 Селекта Байосайенсиз, Инк. ИММУНОНАНОТЕРАПИЯ, ОБЕСПЕЧИВАЮЩАЯ Th1-СМЕЩЕННЫЙ ОТВЕТ
AU2010254180B2 (en) 2009-05-27 2015-08-27 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
US9101541B2 (en) 2010-04-28 2015-08-11 Cadila Healthcare Limited Stable solid pharmaceutical matrix compositions of sirolimus
CN101829061A (zh) * 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法
ES2661978T3 (es) 2010-05-26 2018-04-04 Selecta Biosciences, Inc. Vacunas multivalentes de nanovehículos sintéticos
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
US8912215B2 (en) * 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
WO2013116691A1 (en) * 2012-02-02 2013-08-08 The Washington University Methods for improving muscle strength
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
WO2016007194A1 (en) * 2014-07-10 2016-01-14 Gerald Lee Wolf Companion nanoparticles for theranosis of macrophage-dependent diseases
US20160346221A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
DK3302431T3 (da) 2015-06-04 2020-11-30 Crititech Inc Taxanpartikler og anvendelse deraf
EA036155B1 (ru) 2015-10-16 2020-10-06 Маринус Фармасьютикалс, Инк. Инъекционные составы нейростероида, содержащие наночастицы
US10792477B2 (en) 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
RU2737934C2 (ru) 2016-04-04 2020-12-07 Крититек, Инк. Способы лечения солидных опухолей
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
KR20200014279A (ko) 2017-06-09 2020-02-10 크리티테크, 인크. 항신생물 입자의 낭내 주사에 의한 상피낭종의 치료
SG10201913400QA (en) 2017-06-14 2020-03-30 Crititech Inc Methods for treating lung disorders
RU2020110399A (ru) 2017-10-03 2021-11-09 Крититек, Инк. Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CN109431997B (zh) * 2018-12-20 2021-06-04 武汉科福新药有限责任公司 一种雷帕霉素局部注射制剂及其制备方法
MX2022001553A (es) 2019-08-05 2022-04-18 Marinus Pharmaceuticals Inc Ganaxolona para su uso en el tratamiento del estado epileptico.
CN114828889A (zh) 2019-12-06 2022-07-29 马瑞纳斯制药公司 用于治疗结节性硬化症的加奈索酮
EP3928772B1 (en) 2020-06-26 2024-06-19 Algiax Pharmaceuticals GmbH Nanoparticulate composition

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2671750A (en) * 1950-09-19 1954-03-09 Merck & Co Inc Stable noncaking aqueous suspension of cortisone acetate and method of preparing the same
US3536074A (en) * 1968-03-29 1970-10-27 Alfred Aufhauser Oral administration of a pill,tablet or capsule
US3959457A (en) * 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
JPS4932056B1 (ja) * 1970-12-22 1974-08-27
US4073943A (en) * 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4001200A (en) * 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4226248A (en) * 1978-10-26 1980-10-07 Manoli Samir H Phonocephalographic device
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4718433A (en) * 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
US4598064A (en) * 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4600531A (en) * 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4639364A (en) * 1984-11-14 1987-01-27 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
US4584130A (en) * 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
FR2608942B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
US5006650A (en) * 1987-02-11 1991-04-09 The Upjohn Company Novel N-1 substituted beta-lactams as antibiotics
US5723147A (en) * 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
AU600094B2 (en) * 1987-02-27 1990-08-02 Upjohn Company, The Antibiotic 2- azetidinones have pyrid -4- one 2-yl- carbonylamino-1-imidazolid-2-one-3-yl sulfonylaminocarbonyl groups at N-1
US5015737A (en) * 1987-07-22 1991-05-14 The Upjohn Company Therapeutically useful beta-lactams
US4844882A (en) * 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
US4929446A (en) * 1988-04-19 1990-05-29 American Cyanamid Company Unit dosage form
US4951673A (en) * 1988-08-19 1990-08-28 Alliance Pharmaceutical Corp. Magnetic resonance imaging with perfluorocarbon hydrides
US5041292A (en) * 1988-08-31 1991-08-20 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
GB8914060D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5116599A (en) * 1989-07-31 1992-05-26 Johns Hopkins Univ. Perfluoro-t-butyl-containing compounds for use in fluorine-19 nmr and/or mri
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
JP2687245B2 (ja) * 1989-09-29 1997-12-08 富士写真フイルム株式会社 磁気記録媒体の製造方法
US5250283A (en) * 1990-03-28 1993-10-05 Molecular Biosystems, Inc. Organic contrast agent analog and method of making same
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
CA2019719A1 (en) * 1990-06-25 1991-12-25 William J. Thompson Mouthwash
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5110606A (en) * 1990-11-13 1992-05-05 Affinity Biotech, Inc. Non-aqueous microemulsions for drug delivery
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5143716A (en) * 1991-02-01 1992-09-01 Unger Evan C Phosphorylated sugar alcohols, Mono- and Di-Saccharides as contrast agents for use in magnetic resonance imaging of the gastrointestinal region
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
US5434143A (en) * 1991-05-10 1995-07-18 Boron Biologicals, Inc. Pharmaceutical compositions comprising phosphite-borane compounds
GB9111580D0 (en) * 1991-05-30 1991-07-24 Wellcome Found Nucleoside derivative
US5442062A (en) * 1991-10-24 1995-08-15 The Upjohn Company Imidazole derivatives and pharmaceutical compositions containing the same
US5292650A (en) * 1991-10-29 1994-03-08 Eli Lilly And Company Preparation of hapalindole-related alkaloids from blue-green algae
ES2148223T3 (es) * 1992-03-23 2000-10-16 Univ Georgetown Taxol encapsulado en liposomas y metodo para su uso.
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5401492A (en) * 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
BR9405798A (pt) * 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5766627A (en) * 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5731334A (en) * 1994-01-11 1998-03-24 The Scripps Research Institute Method for treating cancer using taxoid onium salt prodrugs
DE699079T1 (de) * 1994-03-07 1997-09-25 Dendritech Inc Bioaktive und/oder gezielte dendrimere-konjugate
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US5731355A (en) * 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5593657A (en) * 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5500204A (en) * 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5528328A (en) * 1995-02-21 1996-06-18 O'farrill; Dave Camera filter quick release adapter
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5643552A (en) * 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) * 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5635406A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Stabilized standards and calibrators containing rapamycin and tacrolimus bound to anti-rapamycin and anti-tacrolimus antibodies
KR100400620B1 (ko) * 1995-06-09 2004-02-18 노파르티스 아게 라파마이신유도체
GB9515214D0 (en) * 1995-07-25 1995-09-20 Univ Strathclyde Plant extracts
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5834025A (en) * 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US5631741A (en) * 1995-12-29 1997-05-20 Intel Corporation Electronic carbon paper
WO1997025309A1 (en) * 1996-01-03 1997-07-17 Smithkline Beecham Plc Carbamoyloxy derivatives of mutiline and their use as antibacterials
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
NZ333657A (en) * 1996-07-30 2000-05-26 Novartis Ag A pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin
ES2252780T3 (es) * 1996-08-22 2006-05-16 Jagotec Ag Composiciones que comprenden microparticulas de sustancias insolubles en agua y metodo para su preparacion.
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
SI20424A (sl) * 1998-03-05 2001-06-30 Agouron Pharmaceuticals, Inc. Nepeptidna GnRH sredstva
IL162023A0 (en) * 1998-03-30 2005-11-20 Rtp Pharma Inc Compositions containing microparticles of water-insoluble substances and method for their preparation
US6228985B1 (en) * 1998-05-21 2001-05-08 Schering Corporation Derivatives of aminobenzoic and aminobiphenylcarboxylic acids useful as anti-cancer agents
US5962536A (en) * 1998-07-31 1999-10-05 Komer; Gene Injectable propofol formulations
US6028108A (en) * 1998-10-22 2000-02-22 America Home Products Corporation Propofol composition comprising pentetate
US6140373A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6225311B1 (en) * 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6200085B1 (en) * 1999-03-08 2001-03-13 Stuart Gee Transport system for farm combines and other large vehicles
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics
US6362234B1 (en) * 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane
US6399087B1 (en) * 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
SE530813C2 (sv) * 2007-01-31 2008-09-16 Tolerans Ab Förfarande och anordning vid en rotationshäftmaskin

Similar Documents

Publication Publication Date Title
JP2010280687A5 (ja)
JP2005505568A5 (ja)
Udoh et al. Active anticorrosion and self-healing coatings: A review with focus on multi-action smart coating strategies
CA2460436A1 (en) Stabilization of active agents by formulation into nanoparticulate form
JP2011521776A5 (ja)
TWI534217B (zh) 抗菌抗病毒性組成物及其製造方法
Kong et al. Photocatalytic antibacterial capabilities of TiO2− biocidal polymer nanocomposites synthesized by a surface-initiated photopolymerization
JP2011530401A5 (ja)
Shchukina et al. Nanocontainer-based active systems: from self-healing coatings to thermal energy storage
Roodenko et al. Time-resolved synchrotron XPS monitoring of irradiation-induced nitrobenzene reduction for chemical lithography
Ghosh-Mukerji et al. Selective photocatalysis by means of molecular recognition
JP2011213836A5 (ja)
JP2007144403A (ja) 複合型粒子状光触媒およびその製造方法、並びにそれを用いたコーティング剤、光触媒活性部材
TW200920803A (en) Photocatalytic coating
JP2011511864A5 (ja)
JP2017517900A5 (ja)
Pandey et al. Properties of competitively adsorbed BSA and fibrinogen from their mixture on mixed and hybrid surfaces
Kharlampieva et al. pH-responsive photoluminescent LbL hydrogels with confined quantum dots
US20120288479A1 (en) Cross-Linked Polymer Based Hydrogel Material Compositions, Methods and Applications
JP2007324606A5 (ja)
RU2011126193A (ru) Нагруженный металлом катализатор и способ его приготовления
JP2010092799A (ja) 固体高分子型燃料電池用電極触媒
Hussein The state of the art of nanomaterials and its applications in energy saving
JP2012057155A5 (ja)
Shchukin et al. Urea photosynthesis inside polyelectrolyte capsules: Effect of confined media